Nasal Flu Vaccine for Influenza
(MOSAIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.
Healthy volunteers aged 18 to 65 who do not have chronic medical conditions, do not smoke, and have not recently received a flu vaccine will be enrolled. Participants will have three study visits over approximately one week. At the first visit, participants will be screened, give informed consent, and receive the FluMist vaccine. Nasal swabs and a gentle saline nasal wash will be collected before vaccination and again at two and four days after vaccination.
The samples collected will be used to study changes in immune cells, proteins, and viral activity in the nose using laboratory techniques such as gene expression and protein analysis. This information may help researchers better understand how flu vaccines work at the site where infection begins and may support the development of improved vaccines in the future.
There is no direct medical benefit expected for participants. Participation is voluntary, and all study procedures will be performed by trained clinical staff.
Who Is on the Research Team?
Kevin S Harrod, PhD
Principal Investigator
UAB All Study (Central)
Are You a Good Fit for This Trial?
This trial is for healthy adults aged 18 to 65 who do not smoke, have no chronic medical conditions or recent respiratory infections, and haven't received the current flu vaccine. Pregnant or breastfeeding individuals, those with immune problems, severe allergies to FluMist, or certain other health issues cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the FluMist nasal flu vaccine and undergo baseline nasal sampling
Follow-up
Participants undergo follow-up nasal sampling and safety assessments
What Are the Treatments Tested in This Trial?
Interventions
- FluMist
Trial Overview
The study tests how the nasal spray flu vaccine (FluMist) affects immune responses in the nose of healthy adults. Participants get one dose of FluMist and provide nasal samples before and after vaccination over about a week.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants in this single-arm study will receive the FDA-approved live attenuated influenza vaccine (FluMist) administered intranasally according to standard dosing guidelines. All participants will undergo nasal sampling procedures, including nasal swabs and nasal wash, at baseline prior to vaccination and at approximately 2 and 4 days following vaccination. Samples will be collected to evaluate temporal changes in mucosal immune and epithelial responses using molecular and proteomic analyses. No placebo or comparator intervention is used.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.